Get started
Author

Kenichi Suda

ORCID: 0000-0002-0842-8832
Observed ORCID: 0000-0002-0842-8832
OpenAlex ID: A5113944480
Clinical Significance of Perioperative Minimal Residual Disease Detected by Circulating Tumor DNA in Patients With Lung Cancer With a Long Follow-up Data: An Exploratory Study
2024 · Shuta Ohara, Kenichi Suda, et al. · JTO Clinical and Research Reports · 10
PDF
Pyroptosis: A promising target for lung cancer therapy
2023 · Wensheng Zhou, Lishu Zhao, et al. · Chinese Medical Journal - Pulmonary and Critical Care Medicine · 4
Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status
2025 · Kenichi Suda, Kosuke Fujino, et al. · European Journal of Cardio-Thoracic Surgery · 1
Overexpression of PPM1G promotes cell metabolism and activates the NOTCH signaling pathway in lung adenocarcinoma
2025 · Guangmin Xi, Caibo Zhang, et al. · Translational Lung Cancer Research · 1
Supplementary Table 1 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
Supplementary Figure 6 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
PDF
Supplementary Figure Legend from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
PDF
Data from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
Supplementary Figures 1-3 and Table 1. from CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer
2023 · Kenichi Suda, Isao Murakami, et al.
Supplementary Figure 2 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
PDF
Supplementary Figure 3 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
PDF
Supplementary Figure 4 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
PDF
Supplementary Figure 1 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
PDF
Supplementary Figure 5 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
Data from CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer
2023 · Kenichi Suda, Isao Murakami, et al.
Supplementary Figure 5 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
PDF
Data from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
2023 · Takayuki Nakagawa, Shinji Takeuchi, et al.
Data from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
2023 · Yoshihisa Kobayashi, Yosuke Togashi, et al.
Data from Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
2023 · Kenichi Suda, Isao Murakami, et al.
Supplementary Figure Legends, Table 1 from Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
2023 · Mikihiro Kohno, Tatsuro Okamoto, et al.
Supplementary Figure 2 from Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
2023 · Mikihiro Kohno, Tatsuro Okamoto, et al.
Supplementary Figure 1 from Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
2023 · Mikihiro Kohno, Tatsuro Okamoto, et al.
PDF
CCR Translation for This Article from Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
2023 · Kenichi Suda, Isao Murakami, et al.
Supplementary Figure S1 from Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2
2023 · Masato Terashima, Yosuke Togashi, et al.
Supplementary Figure S2 from Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2
2023 · Masato Terashima, Yosuke Togashi, et al.
Works count: 41
Citation count: 16
H-index: 2
I10-index: 1
Year
Topic
Type